A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis (PREDICT-HP)

  • End date
    Jan 19, 2026
  • participants needed
  • sponsor
    National Jewish Health
Updated on 19 April 2022


Up to 135 patients with hypersensitivity pneumonitis will be enrolled at 5 clinical centers across the United States. Patients will be followed for 24 months to determine if biomarkers in the blood can predict disease progression.


Hypersensitivity pneumonitis is an immunologically mediated form of lung disease, resulting from inhalation exposure to a large variety of antigens. For unknown reasons, a subgroup of patients with HP without a known inciting antigen exposure develops chronic disease with progressive pulmonary fibrosis (the leading cause of death). Accurately identifying patients at risk of disease progression is necessary for prognosis and therapy.

Enrolled subjects will be followed for 24 months and complete 5 visits to one of the study centers. Blood biomarkers will be collected in addition to other clinical data to determine if these biomarkers can predict disease progression.

Condition Hypersensitivity Pneumonitis
Clinical Study IdentifierNCT04844359
SponsorNational Jewish Health
Last Modified on19 April 2022


Yes No Not Sure

Inclusion Criteria

Diagnosis of chronic hypersensitivity pneumonitis for at least 3 months
Age 18 through 85 years
Diagnosis of chronic hypersensitivity pneumonitis by HRCT
Able to understand and sign a written informed consent form
Able to understand the importance of adherence to the study protocol and willing to follow all study requirements

Exclusion Criteria

Not a suitable candidate for enrollment or unlikely to comply with the requirements of this study
Known explanation for the interstitial lung disease
Clinical diagnosis of any connective tissue disease
Listed or expected to receive a lung transplant within 4 months from enrollment
Pregnant women
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note